Plazomicin is effective in a non-human primate pneumonic plague model

Bioorganic and Medicinal Chemistry

Volumn 24, Issue 24, 2016, Pages 6429-6439

  Mega, William M ^a   Doyle Eisele, Melanie ^a   Cass, Robert T ^b   Kostrub, Corwin F ^b   Sherwood, Robert L ^a   Metz, Matthew A ^b   Cirz, Ryan T ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b Former or Current Employees of Achaogen Inc   (United States)

Author keywords

Aminoglycoside; Animal rule; Plague; Plazomicin; Pneumonia; Yersinia pestis

Indexed keywords

CREATININE; PLACEBO; PLAZOMICIN; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; SISOMICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG CLEARANCE; ELIMINATION HALF-LIFE; FEMALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PRIMATE MODEL; VOLUME OF DISTRIBUTION AT STEADY-STATE; YERSINIA PESTIS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CONFORMATION; DISEASE MODEL; DOSE RESPONSE; PLAGUE;

ANIMALS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR CONFORMATION; PLAGUE; SISOMICIN;

EID: 84995529975     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2016.08.049     Document Type: Article

References (45)

1. 1 Aggen, J.B., Armstrong, E.S., Goldblum, A.A., Dozzo, P., Linsell, M.S., Gliedt, M.J., Hildebrandt, D.J., Feeney, L.A., Kubo, A., Matias, R.D., Lopez, S., Gomez, M., Wlasichuk, K.B., Diokno, R., Miller, G.H., Moser, H.E., Antimicrob. Agents Chemother., 54, 2010, 4636.
2. 2 Centers for Disease Control (CDC), Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE): November 2015 Update – CRE Toolkit. http://www.cdc.gov/hai/organisms/cre/cre-toolkit/, 2015 (accessed 25.03.16).
3. 3 Inglesby, T.V., Dennis, D.T., Henderson, D.A., Bartlett, J.G., Ascher, M.S., Eitzen, E., Fine, A.D., Friedlander, A.M., Hauer, J., Koerner, J.F., Layton, M., McDade, J., Osterholm, M.T., O'Toole, T., Parker, G., Perl, T.M., Russell, P.K., Schoch-Spana, M., Tonat, K., JAMA, 283, 2000, 2281.
4. 4 Hinckley, A.F., Biggerstaff, B.J., Griffith, K.S., Mead, P.S., Epidemiol. Infect., 140, 2012, 554.
5. 5 Centers for Disease Control (CDC), Plague in the United States. www.cdc.gov/plague/maps, 2015 (accessed 25.03.16).
6. 6 Avelox. [Prescribing Information], Merck & Co., Inc: Whitehouse Station, NJ, 2015.
7. 7 Levaquin. [Prescribing Information], Janssen Pharmaceuticals, Inc: Titusville, NJ, 2014.
8. 8 U.S.Food and Drug Administration (FDA), CFR – Code of Federal Regulations Title 21. Part 314 Applications for FDA Approval to Market a New Drug. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=314, 2015 (accessed 25.03.16).
9. 9 Doll, J.M., Zeitz, P.S., Ettestad, P., Bucholtz, A.L., Davis, T., Gage, K., Am. J. Trop. Med. Hyg., 51, 1994, 109.
10. 10 Layton, R.C., Brasel, T., Gigliotti, A., Barr, E., Storch, S., Myers, L., Hobbs, C., Koster, F., J. Med. Primatol., 40, 2011, 6.
11. 11 U.S.Food and Drug Administration (FDA), Levofloxacin for Pneumonic Plague: Anti-infective Drugs Advisory Committee Meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM299773.pdf, 2012 (accessed 25.03.16).
12. 12 U.S.Food and Drug Administration (FDA), Summary Minutes of the Anti-Infective Drugs Advisory Committee Meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM305327.pdf, 2012 (accessed 25.03.16).
13. 13 Riddle, V.; Cebrik, D.; Kostrub, C.; Ma, L.; van Wart, S. A.; Hillan, K. J. Presented at 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2013; Berlin, Germany. Poster P918.
14. 14 van Wart, S. A.; Forrest, A.; Drusano, G. L.; Bhavnani, S. M.; Bulik, C. C.; Kostrub, C. F.; Ambrose, P. G.; Louie, A. Presented at 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2013; Berlin, Germany. Poster P914.
15. 15 Aliberti, S., Blasi, F., Zanaboni, A.M., Peyrani, P., Tarsia, P., Gaito, S., Ramirez, J.A., Eur. Respir. J., 36, 2010, 128.
16. 16 Chastre, J., Luyt, C.E., Eur. Respir. Rev., 16, 2007, 40.
17. 17 Paul, J., BMJ, 332, 2006, 1358.
18. 18 Pitt, M. L. M.; Dyer, D. N.; Leffel, E. K.; Holman, K.; Raymond, J.; Hartings, J.; Gamble, S.; Schrager, L. K.; Pelsor, F. R.; MacGill, T.; Hewitt, J. Presented at 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27–30, 2006; San Francisco, CA. Abstract B-576.
19. 19 Lindstedt, S.L., Schaeffer, P.J., Lab. Anim., 36, 2002, 1.
20. 20 U.S.Food and Drug Administration (FDA), CFR – Code of Federal Regulations Title 21. Part 58 Good Laboratory Practice for Nonclinical Laboratory Studies. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=58, 2015 (accessed 03.04.16).
21. 21 Deziel, M.R., Heine, H., Louie, A., Kao, M., Byrne, W.R., Basset, J., Miller, L., Bush, K., Kelly, M., Drusano, G.L., Antimicrob. Agents Chemother., 49, 2005, 5099.
22. 22 Layton, R.C., Mega, W., McDonald, J.D., Brasel, T.L., Barr, E.B., Gigliotti, A.P., Koster, F., PLoS. Negl. Trop. Dis., 5, 2011, e959.
23. 23 Instem, Provantis® Integrated Preclinical Software. http://www.instem.com/solutions/provantis/, 2016 (accessed 03.04.16).
24. 24 Burdet, C., Pajot, O., Couffignal, C., Armand-Lefevre, L., Foucrier, A., Laouenan, C., Wolff, M., Massias, L., Mentre, F., Eur. J. Clin. Pharmacol., 71, 2015, 75.
25. 25 Kiser, T.H., Hoody, D.W., Obritsch, M.D., Wegzyn, C.O., Bauling, P.C., Fish, D.N., Antimicrob. Agents Chemother., 50, 2006, 1937.
26. 26 Lodise, T.P., Sorgel, F., Melnick, D., Mason, B., Kinzig, M., Drusano, G.L., Antimicrob. Agents Chemother., 55, 2011, 1606.
27. 27 Heine, H.S., Chuvala, L., Riggins, R., Hurteau, G., Cirz, R., Cass, R., Louie, A., Drusano, G.L., Antimicrob. Agents Chemother., 57, 2013, 2010.
28. 28 Craig, W.A., Redington, J., Ebert, S.C., J. Antimicrob. Chemother., 27, 1991, 29.
29. 29 Drusano, G.L., Ambrose, P.G., Bhavnani, S.M., Bertino, J.S., Nafziger, A.N., Louie, A., Clin. Infect. Dis., 45, 2007, 753.
30. 30 Almaghrabi, R., Clancy, C.J., Doi, Y., Hao, B., Chen, L., Shields, R.K., Press, E.G., Iovine, N.M., Townsend, B.M., Wagener, M.M., Kreiswirth, B., Nguyen, M.H., Antimicrob. Agents Chemother., 58, 2014, 4443.
31. 31 Kees, M.G., Schaeftlein, A., Haeberle, H.A., Kees, F., Kloft, C., Heininger, A., J. Antimicrob. Chemother., 68, 2013, 1331.
32. 32 Drusano, G.L., Preston, S.L., Fowler, C., Corrado, M., Weisinger, B., Kahn, J., J. Infect. Dis., 189, 2004, 1590.
33. 33 Becker, T.M., Poland, J.D., Quan, T.J., White, M.E., Mann, J.M., Barnes, A.M., West J. Med., 147, 1987, 554.
34. 34 Nau, R., Sorgel, F., Eiffert, H., Clin. Microbiol. Rev., 23, 2010, 858.
35. 35 Thwaites, G.E., Bhavnani, S.M., Chau, T.T., Hammel, J.P., Torok, M.E., van Wart, S.A., Mai, P.P., Reynolds, D.K., Caws, M., Dung, N.T., Hien, T.T., Kulawy, R., Farrar, J., Ambrose, P.G., Antimicrob. Agents Chemother., 55, 2011, 3244.
36. 36 Scotton, P.G., Pea, F., Giobbia, M., Baraldo, M., Vaglia, A., Furlanut, M., Clin. Infect. Dis., 33, 2001, e109.
37. 37 Heine, H. S.; Miller, L.; Halasohoris, S.; Holman, K.; Purcell, B.; Armstrong, E. S.; Feeney, L. A.; Matias, R. D.; Miller, G. H. Presented at 48th Annual Meeting of the Infectious Diseases Society of America (IDSA); October 21–24, 2010; Vancouver, BC, Canada. Poster #210.
38. 38 Heine, H. S.; Chuvala, L.; Riggins, R.; Hurteau, G.; Cass, R.; Cirz, R. Presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 9–12, 2012; San Francisco, CA. Abstract B-1302.
39. 39 Mega, W.; Overheim, K.; Cirz, R.; Cass, R.; Valderas, M.; Kuehl, P.; Bruse, K.; Russell, R. Presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 10–13, 2013; Denver, CO. Poster B-1058.
40. 40 Reyes, N.; McKinnell, J. V.; Matias, R. D.; Feeney, L. A.; Cass, R.; Cirz, R. Presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17–20, 2011; Chicago, IL. Poster #A2-045c.
41. 41 Freeman, C.D., Nicolau, D.P., Belliveau, P.P., Nightingale, C.H., J. Antimicrob. Chemother., 39, 1997, 677.
42. 42 Nolen, T.M., Phillips, H.L., Hall, H.J., Rev. Infect. Dis., 7, 1985, S666.
43. 43 Schentag, J.J., Vari, A.J., Winslade, N.E., Swanson, D.J., Smith, I.L., Simons, G.W., Vigano, A., Am. J. Med., 78, 1985, 34.
44. 44 Rodriguez, J.R., Ramirez-Ronda, C.H., Nevarez, M., Antimicrob. Agents Chemother., 27, 1985, 246.
45. 45 Stankowicz, M.S., Ibrahim, J., Brown, D.L., Am. J. Health Syst. Pharm., 72, 2015, 1357.